0.023117
0.000000
0.010877
0.000000
0.019342
0.000000
0.000000
0.000000
0.024412
0.00000
0.00000
0.00000
Brinen, L.S.
Gillmor, S.A.
Fletterick, R.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
2
90.00
115.20
90.00
43.258
51.700
45.271
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C19 H28 N2 O5
364.436
N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE
WRR-112
peptide-like
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Crystal Structure of Cruzain bound to WRR-112
University of California, San Francisco (THESIS)
Enzyme-ligand Interactions, Inhibition and Specificity
50
80
Chapter 3: X-ray Structures of Complexes of Cruzain with Designed Covalent Inhibitors
1998
US
Protein Sci.
PRCIEI
0795
0961-8368
6
1603
1611
Structural Determinants of Specificity in the Cysteine Protease Cruzain
1997
UK
J.Mol.Biol.
JMOBAK
0070
0022-2836
247
251
259
10.1006/jmbi.1994.0137
The Crystal Structure of Cruzain: a Therapeutic Target for Chagas' Disease
1995
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
298
1
IMAGE PLATE
1997-05-18
MARRESEARCH
SINGLE WAVELENGTH
M
x-ray
1
1.5418
1.0
1.5418
ROTATING ANODE
RIGAKU RU200
22715.133
CRUZAIN
3.4.22.-
CATALYTIC DOMAIN
1
man
polymer
364.436
N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE
1
syn
non-polymer
18.015
water
57
nat
water
cruzipain, cruzaine
no
no
APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN
GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL
DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG
APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN
GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL
DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Trypanosoma
Escherichia
sample
5693
Trypanosoma cruzi
562
Escherichia coli
DH5ALPHA
CHEY
1
2.02
38.98
VAPOR DIFFUSION, HANGING DROP
6.5
0.9M NaCitrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
292
repository
Initial release
Version format compliance
Atomic model
Database references
Derived calculations
Non-polymer description
Structure summary
Version format compliance
1
0
2003-06-10
1
1
2008-04-27
1
2
2011-07-13
same protein, ZYA inhibitor
same protein, ZRA inhibitor
same protein, WRR-99 inhibitor
same protein, WRR-204 inhibitor
same protein, MOR-LEU-HPQ inhibitor
RCSB
Y
RCSB
2000-04-26
REL
REL
RL2
N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE
HOH
water
RL2 IS AN E-64 ANALOG.
RL2 WAS N-(3-CARBOXYOXIRANE-2-CARBONYL)-L-
HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE BEFORE REACTION
WITH THE PROTEASE. DURING REACTION WITH THE PROTEASE,
THE EPOXIDE RING OPENS TO FORM N-[3-CARBOXY-2-HYDROXY-
PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE.
THE SG OF CYS 25 IS THEN LINKED TO THE C2 OF RL2 280
AFTER REACTION.
THERE IS A STOP CODON AFTER RESIDUE 212.
RL2
280
2
RL2
RL2
280
A
WAT
1
3
HOH
HOH
281
A
WAT
2
3
HOH
HOH
282
A
WAT
3
3
HOH
HOH
283
A
WAT
4
3
HOH
HOH
284
A
WAT
5
3
HOH
HOH
285
A
WAT
6
3
HOH
HOH
286
A
WAT
7
3
HOH
HOH
287
A
WAT
8
3
HOH
HOH
288
A
WAT
9
3
HOH
HOH
289
A
WAT
10
3
HOH
HOH
290
A
WAT
11
3
HOH
HOH
291
A
WAT
12
3
HOH
HOH
292
A
WAT
13
3
HOH
HOH
293
A
WAT
14
3
HOH
HOH
294
A
WAT
15
3
HOH
HOH
295
A
WAT
16
3
HOH
HOH
296
A
WAT
17
3
HOH
HOH
297
A
WAT
18
3
HOH
HOH
298
A
WAT
19
3
HOH
HOH
299
A
WAT
20
3
HOH
HOH
300
A
WAT
21
3
HOH
HOH
301
A
WAT
22
3
HOH
HOH
302
A
WAT
23
3
HOH
HOH
303
A
WAT
24
3
HOH
HOH
304
A
WAT
25
3
HOH
HOH
305
A
WAT
26
3
HOH
HOH
306
A
WAT
27
3
HOH
HOH
307
A
WAT
28
3
HOH
HOH
308
A
WAT
29
3
HOH
HOH
309
A
WAT
30
3
HOH
HOH
310
A
WAT
31
3
HOH
HOH
311
A
WAT
32
3
HOH
HOH
312
A
WAT
33
3
HOH
HOH
313
A
WAT
34
3
HOH
HOH
314
A
WAT
35
3
HOH
HOH
315
A
WAT
36
3
HOH
HOH
316
A
WAT
37
3
HOH
HOH
317
A
WAT
38
3
HOH
HOH
318
A
WAT
39
3
HOH
HOH
319
A
WAT
40
3
HOH
HOH
320
A
WAT
41
3
HOH
HOH
321
A
WAT
42
3
HOH
HOH
322
A
WAT
43
3
HOH
HOH
323
A
WAT
44
3
HOH
HOH
324
A
WAT
45
3
HOH
HOH
325
A
WAT
46
3
HOH
HOH
326
A
WAT
47
3
HOH
HOH
327
A
WAT
48
3
HOH
HOH
328
A
WAT
49
3
HOH
HOH
329
A
WAT
50
3
HOH
HOH
330
A
WAT
51
3
HOH
HOH
331
A
WAT
52
3
HOH
HOH
332
A
WAT
53
3
HOH
HOH
333
A
WAT
54
3
HOH
HOH
334
A
WAT
55
3
HOH
HOH
335
A
WAT
56
3
HOH
HOH
336
A
WAT
57
3
HOH
HOH
337
A
ALA
1
n
1
ALA
1
A
PRO
2
n
2
PRO
2
A
ALA
3
n
3
ALA
3
A
ALA
4
n
4
ALA
4
A
VAL
5
n
5
VAL
5
A
ASP
6
n
6
ASP
6
A
TRP
7
n
7
TRP
7
A
ARG
8
n
8
ARG
8
A
ALA
9
n
9
ALA
9
A
ARG
10
n
10
ARG
10
A
GLY
11
n
11
GLY
11
A
ALA
12
n
12
ALA
12
A
VAL
13
n
13
VAL
13
A
THR
14
n
14
THR
14
A
ALA
15
n
15
ALA
15
A
VAL
16
n
16
VAL
16
A
LYS
17
n
17
LYS
17
A
ASP
18
n
18
ASP
18
A
GLN
19
n
19
GLN
19
A
GLY
20
n
20
GLY
20
A
GLN
21
n
21
GLN
21
A
CYS
22
n
22
CYS
22
A
GLY
23
n
23
GLY
23
A
SER
24
n
24
SER
24
A
CYS
25
n
25
CYS
25
A
TRP
26
n
26
TRP
26
A
ALA
27
n
27
ALA
27
A
PHE
28
n
28
PHE
28
A
SER
29
n
29
SER
29
A
ALA
30
n
30
ALA
30
A
ILE
31
n
31
ILE
31
A
GLY
32
n
32
GLY
32
A
ASN
33
n
33
ASN
33
A
VAL
34
n
34
VAL
34
A
GLU
35
n
35
GLU
35
A
CYS
36
n
36
CYS
36
A
GLN
37
n
37
GLN
37
A
TRP
38
n
38
TRP
38
A
PHE
39
n
39
PHE
39
A
LEU
40
n
40
LEU
40
A
ALA
41
n
41
ALA
41
A
GLY
42
n
42
GLY
42
A
HIS
43
n
43
HIS
43
A
PRO
44
n
44
PRO
44
A
LEU
45
n
45
LEU
45
A
THR
46
n
46
THR
46
A
ASN
47
n
47
ASN
47
A
LEU
48
n
48
LEU
48
A
SER
49
n
49
SER
49
A
GLU
50
n
50
GLU
50
A
GLN
51
n
51
GLN
51
A
MET
52
n
52
MET
52
A
LEU
53
n
53
LEU
53
A
VAL
54
n
54
VAL
54
A
SER
55
n
55
SER
55
A
CYS
56
n
56
CYS
56
A
ASP
57
n
57
ASP
57
A
LYS
58
n
58
LYS
58
A
THR
59
n
59
THR
59
A
ASP
60
n
60
ASP
60
A
SER
61
n
61
SER
61
A
GLY
62
n
62
GLY
62
A
CYS
63
n
63
CYS
63
A
SER
64
n
64
SER
64
A
GLY
65
n
65
GLY
65
A
GLY
66
n
66
GLY
66
A
LEU
67
n
67
LEU
67
A
MET
68
n
68
MET
68
A
ASN
69
n
69
ASN
69
A
ASN
70
n
70
ASN
70
A
ALA
71
n
71
ALA
71
A
PHE
72
n
72
PHE
72
A
GLU
73
n
73
GLU
73
A
TRP
74
n
74
TRP
74
A
ILE
75
n
75
ILE
75
A
VAL
76
n
76
VAL
76
A
GLN
77
n
77
GLN
77
A
GLU
78
n
78
GLU
78
A
ASN
78
n
79
A
ASN
78
A
ASN
78
n
80
B
ASN
78
A
GLY
78
n
81
C
GLY
78
A
ALA
79
n
82
ALA
79
A
VAL
80
n
83
VAL
80
A
TYR
81
n
84
TYR
81
A
THR
82
n
85
THR
82
A
GLU
83
n
86
GLU
83
A
ASP
84
n
87
ASP
84
A
SER
85
n
88
SER
85
A
TYR
86
n
89
TYR
86
A
PRO
87
n
90
PRO
87
A
TYR
88
n
91
TYR
88
A
ALA
89
n
92
ALA
89
A
SER
89
n
93
A
SER
89
A
GLY
89
n
94
B
GLY
89
A
GLU
89
n
95
C
GLU
89
A
GLY
90
n
96
GLY
90
A
ILE
91
n
97
ILE
91
A
SER
92
n
98
SER
92
A
PRO
93
n
99
PRO
93
A
PRO
94
n
100
PRO
94
A
CYS
95
n
101
CYS
95
A
THR
96
n
102
THR
96
A
THR
97
n
103
THR
97
A
SER
98
n
104
SER
98
A
GLY
99
n
105
GLY
99
A
HIS
100
n
106
HIS
100
A
THR
101
n
107
THR
101
A
VAL
102
n
108
VAL
102
A
GLY
103
n
109
GLY
103
A
ALA
105
n
110
ALA
105
A
THR
106
n
111
THR
106
A
ILE
107
n
112
ILE
107
A
THR
108
n
113
THR
108
A
GLY
109
n
114
GLY
109
A
HIS
110
n
115
HIS
110
A
VAL
111
n
116
VAL
111
A
GLU
112
n
117
GLU
112
A
LEU
113
n
118
LEU
113
A
PRO
114
n
119
PRO
114
A
GLN
115
n
120
GLN
115
A
ASP
116
n
121
ASP
116
A
GLU
117
n
122
GLU
117
A
ALA
118
n
123
ALA
118
A
GLN
119
n
124
GLN
119
A
ILE
120
n
125
ILE
120
A
ALA
121
n
126
ALA
121
A
ALA
122
n
127
ALA
122
A
TRP
123
n
128
TRP
123
A
LEU
124
n
129
LEU
124
A
ALA
125
n
130
ALA
125
A
VAL
126
n
131
VAL
126
A
ASN
127
n
132
ASN
127
A
GLY
128
n
133
GLY
128
A
PRO
129
n
134
PRO
129
A
VAL
130
n
135
VAL
130
A
ALA
131
n
136
ALA
131
A
VAL
132
n
137
VAL
132
A
ALA
133
n
138
ALA
133
A
VAL
134
n
139
VAL
134
A
ASP
135
n
140
ASP
135
A
ALA
136
n
141
ALA
136
A
SER
139
n
142
SER
139
A
SER
140
n
143
SER
140
A
TRP
141
n
144
TRP
141
A
MET
142
n
145
MET
142
A
THR
143
n
146
THR
143
A
TYR
144
n
147
TYR
144
A
THR
145
n
148
THR
145
A
GLY
146
n
149
GLY
146
A
GLY
147
n
150
GLY
147
A
VAL
148
n
151
VAL
148
A
MET
149
n
152
MET
149
A
THR
151
n
153
THR
151
A
SER
152
n
154
SER
152
A
CYS
153
n
155
CYS
153
A
VAL
154
n
156
VAL
154
A
SER
155
n
157
SER
155
A
GLU
156
n
158
GLU
156
A
GLN
156
n
159
A
GLN
156
A
LEU
157
n
160
LEU
157
A
ASP
158
n
161
ASP
158
A
HIS
159
n
162
HIS
159
A
GLY
160
n
163
GLY
160
A
VAL
161
n
164
VAL
161
A
LEU
162
n
165
LEU
162
A
LEU
163
n
166
LEU
163
A
VAL
164
n
167
VAL
164
A
GLY
165
n
168
GLY
165
A
TYR
166
n
169
TYR
166
A
ASN
167
n
170
ASN
167
A
ASP
167
n
171
A
ASP
167
A
SER
167
n
172
B
SER
167
A
ALA
167
n
173
C
ALA
167
A
ALA
167
n
174
D
ALA
167
A
VAL
168
n
175
VAL
168
A
PRO
169
n
176
PRO
169
A
TYR
170
n
177
TYR
170
A
TRP
171
n
178
TRP
171
A
ILE
172
n
179
ILE
172
A
ILE
173
n
180
ILE
173
A
LYS
174
n
181
LYS
174
A
ASN
175
n
182
ASN
175
A
SER
176
n
183
SER
176
A
TRP
177
n
184
TRP
177
A
THR
178
n
185
THR
178
A
THR
179
n
186
THR
179
A
GLN
180
n
187
GLN
180
A
TRP
181
n
188
TRP
181
A
GLY
182
n
189
GLY
182
A
GLU
183
n
190
GLU
183
A
GLU
184
n
191
GLU
184
A
GLY
185
n
192
GLY
185
A
TYR
186
n
193
TYR
186
A
ILE
187
n
194
ILE
187
A
ARG
188
n
195
ARG
188
A
ILE
189
n
196
ILE
189
A
ALA
190
n
197
ALA
190
A
LYS
191
n
198
LYS
191
A
GLY
192
n
199
GLY
192
A
SER
193
n
200
SER
193
A
ASN
198
n
201
ASN
198
A
GLN
199
n
202
GLN
199
A
CYS
200
n
203
CYS
200
A
LEU
201
n
204
LEU
201
A
VAL
202
n
205
VAL
202
A
LYS
203
n
206
LYS
203
A
GLU
204
n
207
GLU
204
A
GLU
205
n
208
GLU
205
A
ALA
206
n
209
ALA
206
A
SER
207
n
210
SER
207
A
SER
208
n
211
SER
208
A
ALA
209
n
212
ALA
209
A
VAL
210
n
213
VAL
210
A
VAL
211
n
214
VAL
211
A
GLY
212
n
215
GLY
212
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
VAL
134
A
N
VAL
139
A
O
HIS
159
A
O
HIS
162
A
N
TYR
166
A
N
TYR
169
A
O
VAL
5
A
O
VAL
5
A
N
VAL
134
A
N
VAL
139
A
O
HIS
159
A
O
HIS
162
A
N
ASN
167
A
N
ASN
170
A
O
TYR
170
A
O
TYR
177
A
N
ILE
173
A
N
ILE
180
A
O
ILE
187
A
O
ILE
194
A
N
ALA
190
A
N
ALA
197
A
O
MET
149
A
O
MET
152
A
O
VAL
80
A
O
VAL
83
A
N
GLY
103
A
N
GLY
109
A
N
VAL
111
A
N
VAL
116
A
O
SER
208
A
O
SER
211
1
6.76
0.80
106.30
113.06
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
7
7
7
N
1
-6.03
0.80
107.30
101.27
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
7
7
7
N
1
6.13
0.80
106.30
112.43
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
26
26
26
N
1
-5.68
0.80
107.30
101.62
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
26
26
26
N
1
6.89
0.80
106.30
113.19
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
38
38
38
N
1
-6.02
0.80
107.30
101.28
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
38
38
38
N
1
6.06
0.80
106.30
112.36
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
74
74
74
N
1
-5.59
0.80
107.30
101.71
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
74
74
74
N
1
6.38
0.80
106.30
112.68
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
123
123
123
N
1
-8.36
1.30
127.00
118.64
A
A
A
CB
CG
CD1
TRP
TRP
TRP
123
123
123
N
1
-5.85
0.80
107.30
101.45
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
123
123
123
N
1
5.96
0.80
106.30
112.26
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
141
141
141
N
1
-5.33
0.80
107.30
101.97
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
141
141
141
N
1
6.37
0.80
106.30
112.67
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
171
171
171
N
1
-5.74
0.80
107.30
101.56
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
171
171
171
N
1
6.24
0.80
106.30
112.54
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
177
177
177
N
1
-5.75
0.80
107.30
101.55
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
177
177
177
N
1
6.16
0.80
106.30
112.46
A
A
A
CD1
CG
CD2
TRP
TRP
TRP
181
181
181
N
1
-5.33
0.80
107.30
101.97
A
A
A
CE2
CD2
CG
TRP
TRP
TRP
181
181
181
N
1
A
A
NE2
CD2
HIS
HIS
43
43
-0.066
0.011
1.373
1.307
N
1
A
A
NE2
CD2
HIS
HIS
110
110
-0.067
0.011
1.373
1.306
N
1
A
PRO
2
-5.96
-67.18
1
A
THR
178
68.36
171.76
PARAM19SG.PRO
TOHP19SG2.PRO
PARAM19.SOL
TOPH19.SOL
INHIB112.TPX
EPOX.TPX
10.9
0.00
0.00
0.00
0.00
0.00
0.00
0.206
0.009
0.173
0.18
0.173
2.00
25.00
570
11819
11819
4.8
95.8
RANDOM
10000000.00
0.00
1
RESTRAINED
THROUGHOUT
0.0
-3.0
toph19 and param19
0.24
0.19
5.00
0.19
0.16
2.00
25.00
57
1676
26
0
1593
0.012
2.4
25.9
0.94
0.234
0.026
0.209
2.13
82
1790
6
4.4
92.5
5.5
2.0
30.0
1EWM
11831
11831
0
-3.0
0.094
1
6.0
2.75
95.8
0.167
2.00
2.07
1139
1
2.8
91.3
data reduction
DENZO
data scaling
SCALEPACK
phasing
AMoRE
refinement
X-PLOR
3.843
CRUZAIN (E.C.3.4.22.-)
THE CYSTEINE PROTEASE CRUZAIN BOUND TO WRR-112
1
N
N
2
N
N
3
N
N
the biological assembly is the monomer found in the asymmetric unit
A
ARG
8
A
ARG
8
HELX_P
A
GLY
11
A
GLY
11
5
1
4
A
SER
24
A
SER
24
HELX_P
A
ALA
41
A
ALA
41
1
2
18
A
SER
49
A
SER
49
HELX_P
A
ASP
57
A
ASP
57
1
3
9
A
SER
61
A
SER
61
HELX_P
A
GLY
65
A
GLY
65
5
4
5
A
ASP
116
A
ASP
121
HELX_P
A
GLY
128
A
GLY
133
1
6
13
A
SER
140
A
SER
143
HELX_P
A
TYR
144
A
TYR
147
5
7
5
A
ASN
198
A
ASN
201
HELX_P
A
VAL
202
A
VAL
205
5
8
5
disulf
2.035
A
CYS
22
A
SG
CYS
22
1_555
A
CYS
63
A
SG
CYS
63
1_555
disulf
2.017
A
CYS
56
A
SG
CYS
56
1_555
A
CYS
95
A
SG
CYS
101
1_555
disulf
2.025
A
CYS
153
A
SG
CYS
155
1_555
A
CYS
200
A
SG
CYS
203
1_555
covale
1.827
A
CYS
25
A
SG
CYS
25
1_555
A
RL2
280
B
C2
RL2
1_555
HYDROLASE/HYDROLASE INHIBITOR
cruzain, cruzipain, drug design, covalent inhibitor, cysteine protease, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
CYSP_TRYCR
UNP
1
123
P25779
APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN
GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL
DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG
123
337
1EWM
1
212
P25779
A
1
1
215
3
5
2
2
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
parallel
anti-parallel
anti-parallel
A
VAL
130
A
VAL
135
A
VAL
134
A
VAL
139
A
HIS
159
A
HIS
162
A
ASN
167
A
ASN
170
A
ALA
4
A
ALA
4
A
ASP
6
A
ASP
6
A
VAL
130
A
VAL
135
A
VAL
134
A
VAL
139
A
HIS
159
A
HIS
162
A
ASN
167
A
ASN
170
A
TYR
170
A
TYR
177
A
LYS
174
A
LYS
181
A
TYR
186
A
TYR
193
A
ALA
190
A
ALA
197
A
VAL
148
A
VAL
151
A
MET
149
A
MET
152
A
ALA
79
A
ALA
82
A
TYR
81
A
TYR
84
A
VAL
102
A
VAL
108
A
THR
106
A
THR
111
A
GLY
109
A
GLY
114
A
GLU
112
A
GLU
117
A
SER
207
A
SER
210
A
VAL
210
A
VAL
213
BINDING SITE FOR RESIDUE RL2 A 280
Software
11
A
GLN
19
A
GLN
19
11
1_555
A
GLY
23
A
GLY
23
11
1_555
A
SER
24
A
SER
24
11
1_555
A
CYS
25
A
CYS
25
11
1_555
A
TRP
26
A
TRP
26
11
1_555
A
SER
61
A
SER
61
11
1_555
A
GLY
65
A
GLY
65
11
1_555
A
GLY
66
A
GLY
66
11
1_555
A
MET
68
A
MET
68
11
1_555
A
ASP
158
A
ASP
161
11
1_555
A
HIS
159
A
HIS
162
11
1_555
4
P 1 21 1